Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.30 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23638606 | 1.00 | OPRM1 (0.32) | OPRM1GPR84NR5A2NR5A1 | |
| SCHEMBL23082851 | 0.72 | GPR84 (0.30) | GPR84 | |
| SCHEMBL25017716 | 0.70 | GAA (0.36) | GPR84 | |
| SCHEMBL18948468 | 0.69 | GAA (0.43) | GPR84 | |
| SCHEMBL30437973 | 0.66 | GPR84 (0.35) | OPRM1GPR84 | |
| SCHEMBL22930730 | 0.65 | POLB (0.37) | — | |
| SCHEMBL23545046 | 0.62 | LMNA (0.35) | OPRM1GPR84 | |
| SCHEMBL22822884 | 0.61 | OPRM1 (0.36) | OPRM1GPR84 | |
| SCHEMBL11305095 | 0.58 | OPRM1 (0.44) | OPRM1GPR84 | |
| SCHEMBL8973166 | 0.58 | OPRM1 (0.39) | OPRM1GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210213006-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES | Seal Rock Therapeutics, Inc. | 2021-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210213006-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES | SNCA, MAPT, HTT | OPRM1 4013/4885GPR84 4586/4885NR5A2 4340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.